Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors

被引:16
作者
Peng, Cheng-Kang [1 ]
Zeng, Ting [1 ]
Xu, Xing-Jun [1 ]
Chang, Yi-Qun [1 ]
Hou, Wen [1 ]
Lu, Kuo [1 ]
Lin, Hui [1 ]
Sun, Ping-Hua [1 ]
Lin, Jing [1 ]
Chen, Wei -Min [1 ]
机构
[1] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China
关键词
Furan-2(5H)-one; alpha; beta-unsaturated lactones; Topoisomerase I; Antitumor; DNA TOPOISOMERASES; CANCER; MECHANISM; LACTONES; AGENTS; CELLS; CHEMOTHERAPY; ALPHA;
D O I
10.1016/j.ejmech.2016.12.035
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, two series of novel 4-(4-substitute damidobenzyl)furan-2(5H)-one derivatives containing an alpha,(beta-unsaturated lactone fragment were synthesized and screened for Topo I inhibition and antitumor activity. The topoisomerase I inhibitory activities and cytotoxicities against three human cancer cell lines (MCF-7,Hela,A549) were evaluated. The results revealed that series 2, compounds bearing an exocyclic double bond on the furanone ring, generally showed more potent activity than series 1, compounds lacking an exocyclic double bond. Several compounds of series 2 possess significant Topo I inhibitory activity and potent antiproliferative activity against cancer cell lines. Further mechanism studies of the most active compound of series 2 (B-15) indicated that synthetic compounds can not only stabilize the drug-enzyme-DNA covalent ternary complex as well as camptothecin, but also interfere with the binding between Topo I and DNA. The binding patterns of these compounds with Topo I and structure-activity relationships are discussed. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:187 / 199
页数:13
相关论文
共 32 条
  • [1] Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors
    Beretta, Giovanni Luca
    Perego, Paola
    Zunino, Franco
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (10) : 1243 - 1256
  • [2] Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A
    Bielawski, Krzysztof
    Winnicka, Katarzyna
    Bielawska, Anna
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (07) : 1493 - 1497
  • [3] Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I
    Boege, F
    Straub, T
    Kehr, A
    Boesenberg, C
    Christiansen, K
    Andersen, A
    Jakob, F
    Kohrle, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (04) : 2262 - 2270
  • [4] Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
    Braun, Michael S.
    Richman, Susan D.
    Quirke, Philip
    Daly, Catherine
    Adlard, Julian W.
    Elliott, Faye
    Barrett, Jennifer H.
    Selby, Peter
    Meade, Angela M.
    Stephens, Richard J.
    Parmar, Mahesh K. B.
    Seymour, Matthew T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2690 - 2698
  • [5] ALPHA-CHLORO-ENAMINES .4. AMINATED HETEROCYCLES FROM REACTION OF PHOSGENE WITH SUBSTITUTED ACETAMIDES
    BUYLE, R
    VIEHE, HG
    [J]. TETRAHEDRON, 1969, 25 (16) : 3453 - &
  • [6] Case D., 2014, AMBER, V14
  • [7] DNA topoisomerases: Structure, function, and mechanism
    Champoux, JJ
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 : 369 - 413
  • [8] A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat
    Cheatham, TE
    Cieplak, P
    Kollman, PA
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 1999, 16 (04) : 845 - 862
  • [9] EUKARYOTIC DNA TOPOISOMERASES-I
    GUPTA, M
    FUJIMORI, A
    POMMIER, Y
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1995, 1262 (01): : 1 - 14
  • [10] Novel securinine derivatives as topoisomerase I based antitumor agents
    Hou, Wen
    Wang, Zhen-Ya
    Peng, Cheng-Kang
    Lin, Jing
    Liu, Xin
    Chang, Yi-Qun
    Xu, Jun
    Jiang, Ren-Wang
    Lin, Hui
    Sun, Ping-Hua
    Chen, Wei-Min
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 122 : 149 - 163